A Phase 1 Study To Evaluate The Pharmacokinetics Of Ag-013736 In Subjects With Impaired Hepatic Function.

Status: Completed

Phase of Trial: Phase I

Latest Information Update: 11 Feb 2019

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Axitinib (Primary)
Indications Colorectal cancer; Liver cancer; Renal cancer; Solid tumours; Thyroid cancer
Focus Adverse reactions; Pharmacokinetics
Sponsors Pfizer

11 Jan 2019 Results characterizing the physiological and molecular characteristics driving variability in axitinib AUCSS using physiologically based pharmacokinetic modeling using data from Pfizer trials (A4061019, A406010, A4061022, A4061036, A4061044, A4061055, A406105) published in the Journal of Clinical Pharmacology
12 Mar 2016 Results assessing pharmacokinetics from this other trial presented at the 117th Annual Meeting of the American Society for Clinical Pharmacology and Therapeutics
21 Nov 2008 Actual start date changed from June 2008 to May 2008, actual end date reported as October 2008 by ClinicalTrials.gov.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com